Full Title
Phase 1 Trial of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RP-3467 Alone and in Combination with Olaparib in Participants with Advanced Solid Tumors (POLAR Trial)Purpose
Researchers want to find the best dose of RP-3467 to give alone and with olaparib in people with solid tumors. The people in this study have advanced solid tumors containing certain genetic changes.
RP-3467 is a type of drug called a polymerase-theta inhibitor. Polymerase-theta is an enzyme designed to repair damaged DNA in cancer cells. By blocking this enzyme, polymerase-theta inhibitors can prevent cancer cells from repairing their DNA. This leads to a buildup of damaged DNA in the cancer cells, possibly causing them to die.
If you join this study, you will get RP-3467 alone or with olaparib. Both drugs are taken orally (by mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have advanced ovarian, pancreatic, breast, or prostate cancer that keeps growing even after treatment.
- Have a mutation (genetic change) in the BRCA1, BRCA2, PALB2, or RAD51B/C/D genes or have homologous recombination deficiency.
- Have recovered from the serious side effects of prior anti-cancer treatments before getting the study therapy.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call 646-888-4226.